Rockwell Medical withdraws 2026 financial guidance on expected acquisition costs
RMTI•Rockwell Medical withdrew its 2026 sales, profitability and operating cash flow guidance, citing expected transaction and financing expenses tied to its proposed acquisition. The combined business could generate annual revenue of $400 million to $450 million; the acquisition has a $125 million base price and up to $45 million in milestone payments, with closing expected in mid-2027.
1. Guidance withdrawn
Rockwell Medical withdrew its 2026 sales, profitability and operating cash flow guidance, citing expected transaction and financing expenses tied to its proposed acquisition of Vantive’s hemodialysis business.
2. Acquisition details
The proposed acquisition has a $125 million base price, with up to $45 million in additional milestone payments. The combined business could generate annual revenue of $400 million to $450 million, subject to operating performance, exchange rates, market conditions and successful integration. Closing is expected in mid-2027, subject to regulatory approvals and other closing conditions.
